New Pathways to Early Detection and Intervention in Alzheimer’s Disease

Saturday, May 30, 2026, at 10:00 a.m.

Program Overview

This series of caregiver communication virtual summit meetings is a dynamic satellite symposium designed to equip neurologists, primary care professionals (PCPs), geriatricians, psychiatrists, neuroradiologists, nurses, nurse practitioners (NPs), and physician assistants (PAs) with practical, evidence-based strategies to enhance the early identification and management of mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Faculty will present integrated approaches to screening, diagnosis, and staging that combine clinical evaluation with objective cognitive and biomarker testing, alongside current clinical practice recommendations for disease-modifying therapies (DMTs), including appropriate patient selection and the monitoring and management of adverse events such as amyloid-related imaging abnormalities (ARIA). A highlight of this summit is a live caregiver discussion, featuring an Alzheimer’s disease caregiver in conversation with a specialist, offering real-world insight into the patient and family experience and deepening understanding of effective caregiver communication. Emphasizing multidisciplinary collaboration and shared decision-making, the program supports clinicians in delivering timely, compassionate, and patient-centered care across the continuum of Alzheimer’s disease.

Target Audience

This activity is designed to meet the educational needs of neurologists, PCPs, geriatricians, psychiatrists, neuroradiologists, nurses, NPs, and PAs.

Learning Objectives

Upon the completion of this program, attendees should be able to:

• Implement evidence-based strategies for screening, diagnosing, and staging MCI and AD that integrate clinical assessment with objective cognitive and biomarker testing

• Apply the latest clinical practice recommendations for the use of DMTs for AD, including criteria for appropriate patient selection

• Develop strategies to identify, monitor, and manage adverse events associated with DMTs for AD, particularly ARIA

• Formulate best practices for a multidisciplinary approach that incorporates shared decision-making when discussing the treatment options and management of AD

Learn more and register here